CHICAGOâ€”Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell heard the latest at the American Society of Clinical Oncologyâ€™s 2013 meeting in Chicago from Dr. Mario Sznol MD, Clinical Research Program Leader at Yale Cancer Center, New Haven, CT and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
You may also like...
Two Drug Combination Doubled Kidney Cancer Progression Free Survival 7 Nov, 2018 Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer 8 Jun, 2018 Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma 13 Oct, 2016 Metastatic renal cell carcinoma: biomarkers to guide future therapy 25 Feb, 2014
- Previous story Combination immunotherapy improved overall survival in patients with metastatic melanoma
- Next story Novel oral anticoagulants: latest opinion from the ESC congress
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014